TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) and Biolojic Design Ltd. ('Biolojic'), a biotechnology company that uses computational biology and artificial intelligence to transform antibodies into intelligent medicinal solutions, today announced an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of Atopic Dermatitis and Asthma..

以色列特拉维夫——（商业新闻短讯）——Teva Pharmaceutical Industries Ltd.（纽约证券交易所和塔斯社：Teva）和Biolojic Design Ltd.（Biolojic），这是一家利用计算生物学和人工智能将抗体转化为智能药物解决方案的生物技术公司，今天宣布了一项独家许可协议，开发一种潜在的新型抗体疗法，用于治疗特应性皮炎和哮喘。。

BD9 is a dual specific antibody that can block both TSLP (Thymic stromal lymphopoietin) and IL-13, and has the potential to deliver treatment across typically TH2-driven inflammatory diseases, such as atopic dermatitis and asthma. Existing drugs currently approved by health authorities focus on only one of these two drivers of inflammation, and do not respond to pathway dynamics.

BD9是一种双特异性抗体，可阻断TSLP（胸腺基质淋巴细胞生成素）和IL-13，并有可能治疗典型的TH2驱动的炎症性疾病，如特应性皮炎和哮喘。目前卫生当局批准的现有药物仅关注这两种炎症驱动因素中的一种，对途径动力学没有反应。

When TSLP or IL13 is upregulated BD9 can bind to either target with both arms and with high affinity, therefore having the potential to help more patients and improve outcomes..

当TSLP或IL13上调时，BD9可以用双臂和高亲和力与任一靶标结合，因此有可能帮助更多患者并改善预后。。

This agreement supports one of Teva’s key pillars in its Pivot to Growth strategy announced in May 2023, to step up innovation, by enhancing the Company’s early-stage pipeline organically and through strategic partnerships.

该协议支持梯瓦2023年5月宣布的“转向增长”战略中的一个关键支柱，即通过有机地和通过战略合作伙伴关系加强公司的早期管道，加快创新。

Richard Francis, Teva’s President and CEO: “Our Pivot to Growth strategy is opening a new era for Teva as we step up innovation and accelerate development of novel therapies in our immunology pipeline powered both by our inherent antibody engineering capabilities and exciting partnerships. Based on the size of the indications and validity of the targets, this collaboration with Biolojic presents an incredible opportunity to bring this treatment to many patients.

理查德·弗朗西斯，Teva总裁兼首席执行官：“我们的增长战略为Teva开启了一个新时代，我们通过固有的抗体工程能力和令人兴奋的合作伙伴关系，在我们的免疫学管道中加快创新和新疗法的开发。基于适应症的规模和目标的有效性，与Biolojic的合作为实现这一目标提供了一个令人难以置信的机会对许多患者的治疗。

As BD9 can tune itself to the specific underlying conditions of the disease and potentially help more patients who do not respond to current therapies and improve outcomes for existing responders and thus addressing a large unmet need.'.

因为BD9可以调整自身以适应疾病的特定潜在条件，并可能帮助更多对当前疗法无反应的患者，并改善现有应答者的预后，从而解决大量未满足的需求。”。

Yanay Ofran, Ph.D., CEO and founder of Biolojic Design: 'We are excited about the opportunity to work with Teva and bring hope to patients. The potential therapy we designed for Atopic Dermatitis and Asthma is another example of how AI can revolutionize drug development. Biolojic’s AI platform allows us to rethink and reimagine what drugs can do.

Biolojic Design首席执行官兼创始人Yanay Ofran博士说：“我们很高兴有机会与Teva合作，为患者带来希望。我们为特应性皮炎和哮喘设计的潜在疗法是AI如何彻底改变药物开发的另一个例子。Biolojic的人工智能平台使我们能够重新思考和想象药物的作用。

Our platform has already yielded the first AI designed antibody that entered the clinic. As Biolojic continues to focus on developing its internal fully owned pipeline, we are excited that our platform may allow Teva to develop BD9 as a novel therapeutic approach that has the potential to be best-in-class.'.

我们的平台已经产生了第一个进入临床的人工智能设计抗体。随着Biolojic继续专注于开发其内部完全拥有的管道，我们很高兴我们的平台可能允许Teva开发BD9作为一种新的治疗方法，具有成为同类最佳的潜力。”。

Under the terms of the agreement, Teva will receive exclusive rights to develop, manufacture and commercialize BD9 worldwide. In exchange, Biolojic will receive an upfront payment, and will be eligible to receive subsequent milestone payments over the next several years, based on the achievement of certain pre-clinical, clinical, regulatory, and commercial milestones.

根据协议条款，特瓦将获得在全球范围内开发、制造和商业化BD9的专有权。作为交换，Biolojic将获得预付款，并有资格在未来几年内根据某些临床前，临床，监管和商业里程碑的成就获得后续里程碑付款。

Biolojic is also eligible to receive tiered royalties in the mid-single to low-double digit on product sales should Teva successfully commercialize a therapy..

如果Teva成功将一种疗法商业化，Biolojic也有资格在产品销售上获得中单到低两位数的分层版税。。

About Teva

关于Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry.

Teva Pharmaceutical Industries Ltd.（纽约证券交易所和塔斯社：Teva）一个多世纪以来一直在开发和生产改善人们生活的药物。我们是仿制药和创新药物的全球领导者，几乎在每个治疗领域都有超过3500种产品。全世界约有2亿人每天服用Teva药物，并由制药行业最大和最复杂的供应链之一提供服务。

Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of innovative and biopharmaceutical products. Learn more at www.tevapharm.com..

随着我们在仿制药领域的确立，我们拥有重要的创新研究和运营，支持我们不断增长的创新和生物制药产品组合。更多信息，请访问www.tevapharm.com。。

About Biolojic

关于生物学

Biolojic Design is an Israeli company that aims to transform antibodies into intelligent medicinal solutions through AI and computational design. Biolojic’s AI platform generates computationally designed antibodies that bind to predefined epitopes, thus allowing for the design of specific functions: agonism, antagonism and selective binding.

Biolojic Design是一家以色列公司，旨在通过人工智能和计算设计将抗体转化为智能药物解决方案。Biolojic的AI平台产生计算设计的抗体，这些抗体与预定义的表位结合，从而允许设计特定功能：激动作用，拮抗作用和选择性结合。

The platform can generate multi-specific antibodies that act as logic gates executing “and” or “or” function and can serve as molecular switches. Biolojic’s pipeline focuses on autoimmune and immuno-oncology, unlocking validated pathways that address large unmet needs..

该平台可以产生多特异性抗体，作为执行“and”或“or”功能的逻辑门，并可以作为分子开关。Biolojic的管道专注于自身免疫和免疫肿瘤学，解锁了解决大量未满足需求的有效途径。。

Teva Cautionary Note Regarding Forward Looking Statements

Teva关于前瞻性声明的警示说明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements.

本新闻稿包含1995年《私人证券诉讼改革法案》所指的前瞻性声明，这些声明基于管理层当前的信念和期望，并受到已知和未知的重大风险和不确定性的影响，可能会导致我们未来的结果，业绩或成就与此类前瞻性声明中明示或暗示的业绩或成就存在显著差异。

You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance.

您可以通过使用诸如“应该”、“期望”、“预期”、“估计”、“目标”、“可能”、“项目”、“指导”、“打算”、“计划”、“相信”等词语以及与未来经营或财务业绩相关的其他具有类似含义和表达的词语来识别这些前瞻性陈述。

Important factors that could cause or contribute to such differences include risks relating to: our ability to effectively execute our exclusive license agreement with Biolojic; our ability to develop and commercialize a potential novel antibody-based therapy based on Biolojic’s AI-based multibody (BD9) platform for the treatment of Atopic Dermatitis and Asthma; our ability to pay milestone payments under the exclusive license agreement with Biolojic; the risk that we will incur significant costs in connection with the development of the multibody for the treatment of Atopic Dermatitis and Asthma, which may exceed any revenue generated by the product; risks that regulatory approvals and other requirements may delay the development and commercialization of the product; our ability to successfully launch and execute our new Pivot to Growth strategy including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or throu.

可能导致或促成这种差异的重要因素包括以下风险：我们有效执行与Biolojic的独家许可协议的能力；我们能够开发和商业化基于Biolojic基于AI的多体（BD9）平台的潜在新型抗体疗法，用于治疗特应性皮炎和哮喘；我们根据与Biolojic的独家许可协议支付里程碑付款的能力；我们将在开发用于治疗特应性皮炎和哮喘的多体系统方面产生重大成本的风险，这可能超过该产品产生的任何收入；监管批准和其他要求可能会延迟产品开发和商业化的风险；我们有能力成功启动和执行新的增长战略，包括扩大我们的创新和生物仿制药渠道，并将创新药物和生物仿制药组合商业化，无论是有机的还是通过有机的方式。